A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium

Maase, Hans von der; Lehmann, Jan; Gravis, Gwénaëlle; Joensuu, Heikki; Geertsen, P.F.; Gough, Jessica; Chen, G; Kania, Marek

doi:10.1093/annonc/mdl154

Cited by 49 publications

(21 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(7, 8) Further, for patients that fail first-line chemotherapy, no clearly defined second-line option exists and none have definitively been shown to prolong overall survival (OS). (9, 10)…”

Section: Introductionmentioning

confidence: 99%

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy

Ghasemzadeh

Bivalacqua

Hahn

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinum based chemotherapy, which has been the standard of care in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system has led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines, and highlight several additional immunotherapy modalities in early stages of development.

show abstract

Section: Introductionmentioning

confidence: 99%

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy

Ghasemzadeh

Bivalacqua

Hahn

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…There was one toxic death due to neutropenic sepsis. Efficacy, however, was apparently not superior to that of single-agent gemcitabine [40].…”

Section: Doublet Chemotherapymentioning

confidence: 84%

The evolving role of chemotherapy in advanced urothelial cancer

Calabrò

Sternberg²

2007

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Randomized trials have demonstrated that cisplatin-based combination chemotherapy can be considered the standard treatment for fit patients with metastatic urothelial cancer. However, several newer regimens have failed to demonstrate superiority in terms of overall survival when compared to classic methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC). The addition of a third agent to doublet combinations is still uncertain. New drugs including pemetrexed and vinflunine are now being studied for second-line therapy. Progress in the understanding of the molecular biology of bladder cancer and identification of new targeted therapies will provide new opportunities. In addition to newer drug combinations, tailoring of chemotherapy on the basis of molecular characteristics to predict chemosensitivity will provide new challenges.

show abstract

“…over 30 minutes on days 1 and 8 with pemetrexed 500 mg/m 2 administered on day 1 of a 21 day cycle. [19] A phase II trial in patients with advanced non-small cell lung cancer used a 14 day schedule of pemetrexed 500 mg/m 2 and gemcitabine 1500 mg/m 2 administered on day 1. The response rate was 26%, and the most common grade 3 or 4 toxicities were neutropenia (47%), leukopenia (25%), fatigue (25%), and anemia (8%).…”

Section: Discussionmentioning

confidence: 99%

Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma

Richey

Tamboli

et al. 2013

American Journal of Clinical Oncology

View full text Add to dashboard Cite

OBJECTIVE To determine the clinical activity and toxicity of combination pemetrexed and gemcitabine for locally advance and metastatic non-clear cell renal cell carcinoma. METHODS In this phase II study patients were treated with pemetrexed 500 mg/m2 IV infusion over 10 minutes(min) on day one followed immediately by gemcitabine 1500 mg/m2 IV over 30 min on day one, repeated every fourteen days. Planned enrollment was 40 patients. The primary endpoints were response rate and progression free survival (PFS). The secondary endpoints were toxicity and overall survival (OS) in months (mo). RESULTS Between December 2005 and December 2008, 16 patients with locally advanced or metastatic non clear cell renal cell carcinoma were enrolled. The trial was stopped due to lack of response and excessive toxicity. The overall response rate was 6.7% (95% exact CI: 0.2%–31.9%), no patients with renal cell carcinoma responded to therapy. The median number of cycles administered was 4 (range: 1–12 cycles), median PFS was 3.2 mo (95% CI: 1.875–>6 mo), and the 16-week PFS rate was 46.7% (95% CI: 19.8%–100%). The median OS was 23.2 mo (95% CI: 12.9–38.1 mo). The most common grade 3 or 4 toxicities were neutropenia (53%), leukopenia (53%), anemia (13%), fatigue (40%), and renal failure (13%). CONCLUSIONS Patients with non clear cell carcinoma metastatic renal cell carcinoma. The combination of pemetrexed and gemcitabine did not show clinical activity in this cohort of patients with non clear cell renal cell carcinoma.

show abstract

A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium

Abstract: The combination of pemetrexed and gemcitabine had a manageable safety profile. However, efficacy was apparently not superior to that of single-agent gemcitabine.

Cited by 49 publications

References 13 publications

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy

The evolving role of chemotherapy in advanced urothelial cancer

Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About